GT Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by GT Biopharma, Inc. (GTBP) on April 3, 2026. The Company, incorporated in Delaware and listed on The Nasdaq Stock Market, operates as a fully remote organization effective July 1, 2024, with no principal executive office.
Key Financial Metrics
The filing does not provide standard financial statements, revenue, profit, cash flow, or margin data. The only specific financial metric disclosed relates to a new contractual commitment:
- Commitment: Up to approximately $3.8 million over three years for a clinical trial.
- Liquidity/Debt: The filing text does not provide a clear value for current cash balances, debt levels, or liquidity ratios.
Material Changes
The primary material change reported is the entry into a definitive agreement on April 3, 2026, with the Regents of the University of Minnesota. This agreement establishes an Investigator Initiated Clinical Trial for the Company's candidate GTB-5550 (camB7-H3 TriKE®).
Outlook, Risks, and Management Commentary
Outlook and Program Details: The University will sponsor an Investigational New Drug (IND) application (IND 169118) and serve as the sponsor investigator for a Phase 1a/1b clinical trial. The study targets select advanced solid tumors that have failed prior therapy.
Agreement Terms and Risks:
- Duration: The funding covers a three-year period.
- Termination: The agreement may be terminated by either party with 30 days' written notice. The University may terminate immediately for health, welfare, and safety reasons. Termination is also permitted for material breach if not cured within 30 days.
- Intellectual Property: Both the University and the Company retain the right to publish study results.
Key Facts for Investor Verification
- Verify the Company's current cash position to assess the ability to fund the $3.8 million commitment over the next three years.
- Confirm the status of the IND 169118 application and the timeline for the Phase 1a/1b trial initiation.
- Review the full text of the Investigator Initiated Clinical Trial Agreement (Exhibit 10.1) for specific milestones or performance conditions not detailed in the summary.
- Monitor for any future filings regarding the safety or efficacy data from the GTB-5550 trial.